Elevance Health Stock Earnings Reports

Elevance Health reported Q2 2026 results above outlook, driven by favorable benefit expense performance (notably in Medicare Advantage and individual ACA), disciplined expense management, and progress in care management/Carelon. The company raised its 2026 adjusted diluted EPS guidance to at least $27 and reiterated confidence in returning to at least 12% adjusted EPS growth in 2027 off the higher 2026 baseline. Management emphasized enterprise-wide actions: faster, AI-enabled detection of medical cost trend; investments to simplify member experience (Sydney Health, Concierge Care); provider connectivity (Health OS); and expansion of Carelon value-based solutions (including CareBridge). Medicaid remains dynamic — management views 2026 as the trough year for Medicaid margins, maintains a prudent full-year Medicaid margin outlook (~-1.75%), and will selectively exit Medicaid markets where sustainable returns are unlikely. Medicare Advantage performance improved due to deliberate plan design and product mix actions, supporting a path to at least a 2% operating margin for 2026. Individual ACA results were broadly in line with planning but seasonal and prudently not fully extrapolated forward. Carelon is scaling and becoming an increasing contributor over time. The company recorded a $0.80 per-share net below-the-line investment-related benefit in the quarter and intends to deploy it toward one-time, targeted investments in medical cost management, member engagement, provider connectivity, and Carelon capabilities; these are non-recurring in 2026. Operating cash flow guidance was raised to at least $6 billion for 2026. Management stressed discipline in reserving, pricing, and capital deployment, and emphasized that the 2027 outlook is supported by multiple levers across the diversified portfolio rather than any single business.